Article
Asprosin Neutralizing Antibodies as a Treatment for Metabolic Syndrome
2020-09-16
Abstract excerpt
Recently, we discovered a new glucogenic and centrally-acting orexigenic hormone – asprosin. Asprosin is elevated in metabolic syndrome (MS) patients, and importantly, its genetic loss results in reduced appetite, leanness and robust insulin sensitivity, leading to protection from MS. Here we demonstrate that anti-asprosin monoclonal antibodies (mAbs) are a dual-effect pharmacologic therapy that targets the two ke...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- c9bfaed2-2125-5be7-b305-3d13601ae0df
- DOI
- 10.1101/2020.09.15.298489
